Syngene International Reports March Quarter Revenue Of ₹10.37 Billion And Profit Of ₹1.48 Billion

Syngene International, a leading contract research and manufacturing organization, reported its financial results for the March quarter, showcasing resilience in a competitive industry. The company’s consolidated revenue stood at ₹10.37 billion, while net profit reached ₹1.48 billion, reflecting consistent demand for its services.

Revenue And Profit Performance

The revenue growth underscores Syngene’s ability to expand its operations across research, development, and manufacturing. Profitability remained strong, supported by efficient cost management and robust client partnerships in the global pharmaceutical and biotechnology markets.

Industry Context

With increasing demand for outsourced research and biopharma solutions, Syngene continues to strengthen its role as a trusted partner for global healthcare companies. The results highlight its adaptability to evolving industry needs and regulatory frameworks.

Key Highlights

• Consolidated revenue from operations at ₹10.37 billion
• Net profit reported at ₹1.48 billion
• Growth driven by contract research and manufacturing services
• Reinforces Syngene’s leadership in India’s biopharma sector

Sources: Reuters, company filings, industry reports